Abstract
Purpose :
To evaluate the efficacy and safety of the Ultrasonic Circular Cyclo Coagulation (UC3) procedure with a second generation probe.
Methods :
Fifty-two eyes of 52 patients with primary open-angle glaucoma were treated between April 2015 and August 2015 in 4 University Hospitals with a second generation therapy probe comprising 6 piezoelectric transducers with increased lesion volume. All patients were treated with a 8 seconds exposure time. Complete ophthalmic examinations were performed before the procedure, and at 1 day, 1 week, 3 and 6 months after. Primary outcomes were surgical success (defined as intraocular pressure (IOP) reduction from baseline ≥ 20% and IOP > 5mmHg) at the last follow-up visit, and vision-threatening complications. Secondary outcomes were mean IOP at each follow-up visits compared to baseline, medication use, complications, and re-interventions.
Results :
IOP was significantly reduced (p<0.02), from a mean preoperative value of 24.4 ± 6.9 mmHg to a mean value of 15.6 ± 6.7 mmHg at last follow-up. Success (IOP reduction >20%) was achieved in 69% of eyes at last follow-up. No patients were ret-treated. No major intra- operative complications occurred. Transitory hypotony (IOP<5mmHg) occurred in 3 patients, choroidal detachment in 1 patient and macular edema in 1 patient during the follow-up.
Conclusions :
Ultrasonic Circular Cyclo Coagulation seems to be an effective method to reduce intraocular pressure in patients with primary open-angle glaucoma. Increasing the lesion volume seems to increase the efficacy and rate of responders.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.